



## Three steps to help you get started with **ZEPOSIA**

When you begin treatment with ZEPOSIA, you'll have support available to you every step of the way.

A dedicated Support Coordinator can help determine your coverage for ZEPOSIA, what your out-of-pocket costs may be, and other financial options. **Here's what to expect as you get started:**

1



### SUPPORT EVERY STEP OF THE WAY

Once you're prescribed ZEPOSIA, a Support Coordinator will contact you to welcome you to the program and guide you through the support offerings.

#### Our Support Coordinators can:

- Help navigate your insurance benefits\*
- Assist you in exploring available support and savings options
- Arrange for eligible, commercially insured patients to get ZEPOSIA in the event of delays or issues with insurance coverage
- Assist eligible, commercially insured patients with scheduling the routine tests needed to start ZEPOSIA

*If you haven't heard from a Support Coordinator, reach out to your healthcare team to ensure your Start Form was submitted to ZEPOSIA 360 Support.*

2



### INITIAL ROUTINE TESTS TO GET STARTED

Before you start taking ZEPOSIA, two routine tests are required. If you have a history of certain eye conditions (macular edema or uveitis) or diabetes, you may also need an eye exam. Let your healthcare provider know if you've had some of these tests within the last six months, as they may not need to be repeated:



#### Blood work

Including complete blood count and liver function tests



#### An electrocardiogram (ECG)

A common test that uses small sensors to monitor your heart and makes sure it's working normally before you start treatment



**These tests can be completed at your home if you're eligible and commercially insured.** ZEPOSIA 360 Support can help schedule them. **Out-of-pocket costs may be eligible for reimbursement.** There may be costs associated with some of the routine medical tests, but depending on where these tests take place, eligible, commercially insured patients may qualify for reimbursement.

Additional eligibility requirements and terms and conditions apply.†‡



## GET ZEPOSIA DELIVERED AND BEGIN TREATMENT


Once you've been approved to begin treatment, you'll receive the ZEPOSIA Starter Kit.<sup>5</sup> It will either be provided to you by your healthcare team or delivered directly to your home.



### The ZEPOSIA Starter Kit has two parts:

- 1 A 7-day Starter Pack** for your first week of treatment. The pills in this pack help increase your dosage of ZEPOSIA gradually. Each pill is labeled with the day and dosage. Be sure to follow the instructions written on the pack and take the pills in the correct order
- 2 The regular dosage of ZEPOSIA** (orange capsules) you'll begin taking on day 8 (after completing the 7-day Starter Pack)

**You will receive a call from your specialty pharmacy to confirm the delivery of your ZEPOSIA prescription each month.** If you prefer to pick up your prescription in store, simply ask your specialty pharmacy. They may offer that option.



### Have questions about financial assistance or out-of-pocket costs?

Contact our Support Coordinators at **1-833-ZEPOSIA (1-833-937-6742)**, Monday to Friday, 8 AM–8 PM ET.

\*The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any services or item.

†Patient must have a valid prescription for ZEPOSIA for an FDA-approved indication. Patients are not eligible if they have prescription insurance coverage through a state or federal healthcare program, including but not limited to Medicare, Medicaid, Medigap, CHAMPUS, TRICARE, Veterans Affairs (VA), or Department of Defense (DoD) programs, or reside in Rhode Island. To receive the In-Home Medical Services Program, the prescriber must request in-home assessment assistance through the ZEPOSIA 360 Support program. The patient's insurance will not be billed, and the patient will not be responsible for any out-of-pocket costs. Patients who move from commercial plans to state or federal healthcare programs will no longer be eligible. The program cannot be combined with any other offer, rebate, coupon, or free trial. The program is not conditioned on any past, present, or future purchase, including refills. Only valid in the United States and US Territories. Void where prohibited by law, taxed, or restricted. The program is not insurance. Bristol-Myers Squibb Company reserves the right to rescind, revoke, or amend this program at any time without notice. Other limitations may apply.

‡ZEPOSIA Medical Reimbursement Benefit Program is valid only for patients with commercial insurance. The Program includes a medical assessment benefit offer for out-of-pocket costs for the initial blood tests, ECG screening, and eye exam for ZEPOSIA where the full cost is not covered by patient's insurance. Patients are not eligible for the Program if they have insurance coverage for their medical assessment through a state or federal healthcare program, including but not limited to Medicare, Medicaid, Medigap, CHAMPUS, TRICARE, Veterans Affairs (VA), or Department of Defense (DoD) programs, or reside in Massachusetts, Minnesota or Rhode Island. Patients who move from commercial plans to state or federal healthcare programs will no longer be eligible. Patient must be 18 years of age or older. Patients may pay as little as \$0 in out-of-pocket costs for the medical assessment, subject to a maximum benefit of \$2,000. The Program offer only applies to ZEPOSIA clinical baseline assessment services covered by the Program. Patients are responsible for any costs that exceed the maximum amount. To receive the medical assessment benefit, an Explanation of Benefits (EOB) form must be submitted, along with copies of receipts for any payments made. The Program expires on December 31, 2023. All Program payments are for the benefit of the patient only. Patients, pharmacists, and prescribers may not seek reimbursement from health insurance, health savings or flexible spending accounts, or any third party, for any part of the medical assessment benefit received by the patient through this Program. Patient's acceptance of any Program benefit confirms that it is consistent with patient's insurance and that patient will report the value received as may be required by his/her insurance provider. Program valid only in the United States and Puerto Rico. Void where prohibited by law, taxed, or restricted. The Program cannot be combined with any other offer, rebate, coupon, or free trial. The Program is not conditioned on any past, present or future purchase, including refills. The Program is not insurance. Other limitations may apply. Bristol Myers Squibb reserves the right to rescind, revoke, or amend this Program at any time without notice.

<sup>5</sup>Patient must have a valid prescription for ZEPOSIA for an FDA-approved indication. Patient must be new to therapy and have not previously received a sample or filled a prescription for ZEPOSIA. Patient is responsible for applicable taxes, if any. This offer is limited to one use per patient per lifetime and is non-transferable. Cannot be combined with any other rebate/coupon, free trial, or similar offer. No substitutions permitted. Patients, pharmacists, and prescribers cannot seek reimbursement for the ZEPOSIA Free Trial from health insurance or any third party, including state or federally funded programs. Patients may not count the ZEPOSIA Free Trial as an expense incurred for purposes of determining out-of-pocket costs for any plan, including Medicare Part D true out-of-pocket costs (TrOOP). Offer is not conditioned on any past, present, or future purchase, including refills. Only valid in the United States and US Territories. Void where prohibited by law or restricted. The program is not insurance. Bristol Myers Squibb reserves the right to rescind, revoke, or amend this offer at any time without notice.



ZEPOSIA, ZEPOSIA 360 Support, and ZEPOSIA logo are trademarks of Celgene Corporation, a Bristol Myers Squibb company.

© 2023 Bristol-Myers Squibb Company. 2084-US-2300438 06/23

